# Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax

> **NCT02322528** · NA · COMPLETED · sponsor: **University of Rochester** · enrollment: 10 (actual)

## Conditions studied

- Sjogren's Disease

## Interventions

- **DRUG:** Administration of Lotemax

## Key facts

- **NCT ID:** NCT02322528
- **Lead sponsor:** University of Rochester
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2015-10-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02322528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02322528, "Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02322528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*